About us Contacts Drug interactions: 390 212
Drug search by name

Neulasta Onpro Kit and Polatuzumab Vedotin-piiq

Determining the interaction of Neulasta Onpro Kit and Polatuzumab Vedotin-piiq and the possibility of their joint administration.

Check result:
Neulasta Onpro Kit <> Polatuzumab Vedotin-piiq
Relevance: 04.10.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Consumer information for this interaction is not currently available.ADJUST DOSING INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with cancer chemotherapy have not been established. Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while antineoplastic agents primarily target rapidly dividing cells. MANAGEMENT: Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, the manufacturer recommends that pegfilgrastim not be given from 14 days before until 24 hours after administration of antineoplastic agents. References "Product Information. Neulasta (pegfilgrastim)." Amgen, Thousand Oaks, CA.

Professional:

ADJUST DOSING INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with cancer chemotherapy have not been established. Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while antineoplastic agents primarily target rapidly dividing cells.

MANAGEMENT: Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, the manufacturer recommends that pegfilgrastim not be given from 14 days before until 24 hours after administration of antineoplastic agents.

References
  • "Product Information. Neulasta (pegfilgrastim)." Amgen, Thousand Oaks, CA.
Neulasta Onpro Kit

Generic Name: pegfilgrastim

Brand name: Neulasta, Fulphila, Neulasta Onpro Kit, Udenyca, Neulasta Delivery Kit

Synonyms: Neulasta

Polatuzumab Vedotin-piiq

Generic Name: polatuzumab vedotin

Brand name: Polivy

Synonyms: Polatuzumab vedotin, Polatuzumab Vedotin

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle